President and Chief Executive Officer
Rick Fair has a 20-year track record as a strategist and commercial leader in the biopharmaceutical industry. He joined Bellicum as President and CEO in January 2017 from Genentech/Roche where he most recently served as Senior Vice President, Head of Oncology Global Product Strategy, leading oncology product strategy and global commercialization. In this role, he oversaw the global launch of five new molecular entities, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer, and numerous line extensions. He also contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine. Previously, he held several commercial leadership positions within Genentech, including franchise leadership with P&L responsibility for its thrombolytics and oral oncolytics businesses. Prior to Genentech, Mr. Fair spent nine years in the pharmaceutical business at Johnson & Johnson, holding leadership roles in marketing, managed care and reimbursement strategy, and managed care customer management. Mr. Fair received his B.S. from the University of Michigan and his M.B.A. from Columbia Business School.
Chief Operating Officer and Executive Vice President of Clinical Development
Annemarie Moseley joined Bellicum in 2011. She has over 20 years of industry experience in translational medicine and clinical development of stem cell therapies, immunotherapies, biological devices, and combination products, including overseeing the first late-stage Graft versus Host Disease (GvHD) study in patients who underwent hematopoietic stem cell transplant. Dr. Moseley has held CEO positions at Osiris and Cognate Therapeutics, and prior management positions at Guidant, Novartis and Rhone-Polenc Rorer. She completed her M.D., Internal Medicine Residency and Genetics Fellowship at Baylor College of Medicine, Houston and received her Ph.D. from Utah State University in Physiology/Biochemistry.
Chief Financial Officer and Treasurer
Alan Musso joined Bellicum in November 2014 and serves as Chief Financial Officer and Treasurer. He has over 25 years of biotech and pharmaceutical industry experience in both large and emerging growth companies, including capital raising, corporate partnering, finance, strategy and the financial stewardship of publicly-traded companies. He most recently served as Senior Vice President, Finance and Administration, CFO and Treasurer of Targacept, Inc. He began his career working in the public accounting field at KPMG and later held positions of increasing responsibility with Pfizer. Mr. Musso received a B.S. in Accounting from Saint Mary’s College of California, and a master’s degree from the American Graduate School of International Management in Glendale, Arizona.
Chief Scientific Officer
David Spencer joined Bellicum in 2012 as Chief Scientific Officer. Dr. Spencer is the inventor of CID technology, and together with Dr. Slawin, developed the first clinical applications of the technology, DeCIDe® and CaspaCIDe® that are now advancing in human clinical trials. Prior to joining Bellicum, he served as Professor and Vice Chairman of Pathology & Immunology, Baylor College of Medicine, during which time he was a scientific advisor to the Company. Dr. Spencer oversees a robust research program focused on CID clinical applications and supports clinical development of our CID-enabled products. He earned his Ph.D. at Massachusetts Institute of Technology and was a postdoctoral fellow at Stanford University.
Senior Vice President and General Counsel
Ken Moseley joined Bellicum in 2011 as Vice President, Intellectual Property & Legal Affairs. He has more than 20 years of experience as Corporate Counsel and V.P. of Intellectual Property for companies in the cell and gene therapy space, including Osiris Therapeutics, SyStemix and Applied Immune Sciences. He is a registered U.S. patent attorney and is a member of the State Bars of Texas and California.
Senior Vice President of Manufacturing
Alan Smith joined Bellicum in October 2015 with over 30 years of experience in R&D, Manufacturing and Quality roles in cellular therapeutics. Most recently, Dr. Smith served as Vice President of Research & Development and Cellular Therapeutics for LifeNet Health, and its wholly owned subsidiary, The Institute of Regenerative Medicine. Prior to consulting to the cell therapy industry for a number of years, Dr. Smith served as President and Chief Executive Officer for Cognate BioServices, and COO and SVP Research & Development for Osiris Therapeutics. Previously, he led the R&D functions for Aastrom Biosciences and Geneic Sciences, and he served as Director of Cell Separations Research & Development at Baxter Healthcare. He is a former Adjunct Professor at Eastern Virginia Medical School, California State University – Long Beach and Utah State University. Dr. Smith earned his Bachelor of Science in Chemistry at Southern Utah University and his doctorate in Biochemistry at Utah State University.
Vice President of Commercial Planning and Program Management
Scott Cullison joined Bellicum in August 2015 as Vice President of Commercial Planning and Program Management. He brings over 13 years of biotech and pharmaceutical industry experience, including expertise in business development, alliance management, product management, commercialization, R&D program leadership and strategic planning. Throughout his career, Mr. Cullison held positions of increasing responsibility at Targacept, most recently serving as Vice President of Business Development. He received an M.B.A from Wake Forest University and a B.S. in Molecular & Cellular Biology from the University of Arizona.
Vice President of Product Discovery
Aaron Foster is Vice President of Product Discovery at Bellicum Pharmaceuticals. He leads the CAR and TCR gene-modified T cell programs that are developing systems for controlling T cell behavior in vivo using molecular switch technology. Prior to joining Bellicum in 2012, Dr. Foster was an Assistant Professor at Baylor College of Medicine at the Center for Cell and Gene Therapy, where he led a group researching adoptive T cell therapies, cancer vaccines and nanotherapeutics. He received his B.A. in Biology from the University of Puget Sound and his Ph.D. in Chemical Engineering from the University of Sydney.
Vice President of Regulatory Affairs
Martha French joined Bellicum in 2011 with over 25 years combined experience in biomedical research and regulatory affairs. As Director of Regulatory Affairs at InGeneron Inc., she was responsible for the management of European and US regulatory activities for medical devices that prepare autologous regenerative cell therapies at point of care. At Introgen Therapeutics, Martha led US and European pre-market regulatory activities for three novel biologic products. She was responsible for the filing of the first gene therapy Biologics License Application (BLA) to the FDA and filed two gene therapy Marketing Authorization Applications (MAA) to the EMA. At Valentis, Inc. (formerly Gene Medicine Inc.), Ms. French led the Analytical Sciences core teams in support of the company’s cardiovascular, oncology and PEG protein programs. With long tenure at Lark Technologies, as Vice President of Operations, she managed the DNA sequencing, library screening, restriction enzyme mapping and PCR services. Ms. French graduated from Carroll University with a Bachelor of Science in Biology, taught Regulatory Affairs for the 2008 Human Gene Therapy course at the University of Texas Graduate School of Biomedical Sciences.
Vice President of Human Resources
Anne Frese joined Bellicum in March 2015 as Vice President of Human Resources. With over 25 years experience as a global HR leader, she has successfully crossed industry sectors, from engineering and technology to healthcare and consulting. Ms. Frese has led the function from start ups through transformations ensuring the HR strategies underpin and enable the business to achieve its objectives. Having completed over forty acquisitions and integrations throughout Canada, the US and UK, Mrs. Frese has led numerous change and operational excellence initiatives. Mrs. Frese is a graduate of McGill University in Montreal, Quebec, where she obtained her Bachelor of Arts in Labor Relations and Economics. While at McGill she was a teaching assistant in Organizational Behavior and later taught Human Resources Management at Ryerson Polytechnical in Toronto.
Vice President, Viral Vector Development and Manufacturing
Joe Senesac joined Bellicum in 2011 as Vice President, Manufacturing. He has worked in the biotech/pharmaceutical industry for 21 years, with 16 of those years at companies developing cellular and gene-based products. Prior to joining Bellicum, he was Senior Director of Biologics Manufacturing and Development at Intrexon Corporation in Pennsylvania and Maryland. Prior to Intrexon, Mr. Senesac held positions at Introgen Therapeutics, Promega Corporation, and Rhone-Poulenc Rorer, with roles in manufacturing, process development, quality control, and facilities management. He has been responsible for numerous CMC regulatory filings and participated in multiple meetings with the FDA and EMA, including a pre-approval inspection. Mr. Senesac received a B.A. in Chemistry and Economics from Knox College, and an M.B.A. from the University of Colorado at Colorado Springs.
Vice President of Pharmaceutical Development
Steve Toler joined Bellicum in May of 2015 as Vice President of Pharmaceutical Development. He has over 22 years of Pharmaceutical R&D experience, beginning his career with Pfizer in 1993. Most recently, Steve was Vice President of Translational Medicine at Targacept in Winston-Salem, North Carolina. Steve holds a Pharm.D. degree from Mercer University and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky. He completed a residency in Clinical Pharmacy at Chandler Medical Center in Lexington, Kentucky and is Board Certified in Toxicology by the ABT.